Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Delivers On Innovation Agenda In 2021

Revenue At The Chinese Firm Has Increased By 186.3% Year On Year

Executive Summary

Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.

You may also be interested in...



Henlius Denosumab Biosimilar Trial Enters Phase III

Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.

Henlius Speeds Up Efforts On Ophthalmic Bevacizumab

Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.

Henlius Wins Chinese Approval For Rituximab RA Indication

Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.

30

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel